| 1 |
33140501 | dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells. | 2021 Jan |
1 |
| 2 |
33824328 | Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer. | 2021 Apr 6 |
2 |
| 3 |
29748212 | TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy. | 2018 Aug |
1 |
| 4 |
24452393 | First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. | 2014 Mar |
1 |
| 5 |
21780905 | Cellular response to efficient dUTPase RNAi silencing in stable HeLa cell lines perturbs expression levels of genes involved in thymidylate metabolism. | 2011 Jun |
1 |
| 6 |
19015155 | Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. | 2009 Jan |
1 |
| 7 |
8162567 | Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase. | 1994 May 1 |
1 |